RxSight (RXST)

Its main product platform is the Light Adjustable Lens, used together with a proprietary Light Delivery Device. After cataract surgery and healing, the lens can be adjusted non-invasively through targeted ultraviolet light treatments performed in a physician’s office. This process changes the shape and focusing characteristics of the implanted lens, enabling doctors to personalize the final prescription based on the patient’s actual post-surgical visual performance rather than relying solely on pre-surgery measurements.

RxSight serves ophthalmic surgeons, ambulatory surgery centers, and eye-care practices involved in premium cataract procedures. The company’s system is designed for patients who want reduced dependence on glasses or contact lenses after surgery, and it fits into a broader market in which aging populations and demand for advanced vision correction are supporting growth in cataract-related technologies.

The company operates in one primary business segment: the research, development, manufacture, and commercialization of light adjustable lenses and the related capital equipment required to deliver post-operative treatments. As a medical device company, RxSight’s performance depends on surgeon adoption, procedure volumes, reimbursement dynamics, manufacturing execution, and continued clinical confidence in the safety and durability of its lens-adjustment approach.